×
Hero Background

Chiari Malformation Companies

ID: MRFR/Pharma/4177-HCR
105 Pages
Rahul Gotadki
October 2025

Chiari malformation is a condition in which brain tissue extends into the spinal canal, causing structural abnormalities and potentially leading to symptoms such as headaches, neck pain, and coordination problems. While there are no specific companies solely dedicated to Chiari malformation, there are medical device companies, pharmaceutical companies, and healthcare organizations that may be involved in researching, developing treatments, or providing support for individuals with Chiari malformation. 

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Top Industry Leaders in the Chiari Malformation Market

Chiari Malformation Market

 


Latest Chiari Malformation Companies Updates:


Surgeonet's NeuroGlide® Cervical Decompression System Received FDA approval in October 2023 for minimally invasive decompression surgery in patients with Chiari Type I Malformation. This offers an alternative to traditional, more invasive open surgery.


MDI's VentriFlow™ CSF Diversion System Phase 2 trial results presented in November 2023 showed promising effectiveness in managing syringomyelia associated with Chiari Malformation.


Novel Biomarkers Companies are exploring potential biomarkers for early detection and diagnosis of Chiari Malformation, aiming to improve patient outcomes and reduce unnecessary surgeries.


List of Chiari Malformation Key companies in the market:



  • Abbott Laboratories, Inc.

  • Becton, Dickinson and Company

  • Novartis AG

  • Johnson & Johnson

  • Pfizer, Inc.

  • Sanofi-Aventis

  • GlaxoSmithKline